{"id":190993,"date":"2026-10-23T06:20:36","date_gmt":"2026-10-23T06:20:36","guid":{"rendered":"https:\/\/www.europesays.com\/dk\/190993\/"},"modified":"2026-10-23T06:20:36","modified_gmt":"2026-10-23T06:20:36","slug":"h1-partners-with-novo-nordisk-to-scale-ai-driven-clinical-development","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/dk\/190993\/","title":{"rendered":"H1 Partners with Novo Nordisk to Scale AI-Driven Clinical Development"},"content":{"rendered":"<p>    <a href=\"https:\/\/s.yimg.com\/lo\/mysterio\/api\/5cf32b260113ea0b164d92f53ec950936b5990f3b61be1957cfbbd6b7ac276ca\/lightyear_networkapi\/resizefit_w960%3Bquality_80%3Bformat_webp\/https%3A%2F%2Fmedia.zenfs.com%2Fen%2Fglobenewswire.com%2F2aeb6af6b94775ec836296c9b0522b6a\" target=\"_blank\" rel=\"noopener noreferrer nofollow\"><img loading=\"lazy\" decoding=\"async\" src=\"data:image\/gif;base64,R0lGODlhAQABAIAAAAAAAP\/\/\/ywAAAAAAQABAAACAUwAOw==\" alt=\"H1\" height=\"176\" width=\"300\" class=\"yf-1f8hkhu loader\"\/><\/a> H1           <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">Partnership builds on Novo Nordisk&#8217;s AI and digital foundation to enhance clinical trial design and execution through AI-enabled workflows and insights  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">H1 Partners with Novo Nordisk to Scale AI-Driven Clinical Development  <\/p>\n<p>    <a href=\"https:\/\/s.yimg.com\/lo\/mysterio\/api\/2c71db47bf8882679996e15f6a73ef546ffb35822b25f3e62654a18f5d0b7ccc\/lightyear_networkapi\/resizefit_w960%3Bquality_80%3Bformat_webp\/https%3A%2F%2Fmedia.zenfs.com%2Fen%2Fglobenewswire.com%2F6907d5a16754f67ceda2268627632772\" target=\"_blank\" rel=\"noopener noreferrer nofollow\"><img loading=\"lazy\" decoding=\"async\" src=\"data:image\/gif;base64,R0lGODlhAQABAIAAAAAAAP\/\/\/ywAAAAAAQABAAACAUwAOw==\" alt=\"Ariel Katz, CEO of H1\" height=\"720\" width=\"960\" class=\"yf-1f8hkhu loader\"\/><\/a> Ariel Katz, CEO of H1           <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">NEW YORK, Aug. 04, 2026 (GLOBE NEWSWIRE) &#8212; \u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=nFOu-gD46QSbeZWcGk4tsXWU369lT1TzBAjrPpQCT6c_WDpX0m2sor82h0sNinww\" data-ylk=\"slk:H1;elm:context_link;itc:0;sec:content-canvas;source:content-canvas%20default\" data-yga=\"{&quot;yLinkText&quot;:&quot;H1&quot;,&quot;yLinkElement&quot;:&quot;context_link&quot;,&quot;yModuleName&quot;:&quot;content-canvas&quot;,&quot;yTrafficOrigin&quot;:&quot;content-canvas default&quot;}\" target=\"_blank\" rel=\"noopener noreferrer nofollow\">H1<\/a> today announced a new partnership with <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=BPCq0phCgvA6wRs6W4_VrlOlEHC9Mp89N80eOZ5F-GwDjLq2ePnhIsIHlgRXbY8n4bwN1k5XTKVjgSWblqFFIzW2CTb-AcDQNRhgA4CJ92I=\" data-ylk=\"slk:Novo%20Nordisk;elm:context_link;itc:0;sec:content-canvas;source:content-canvas%20default\" data-yga=\"{&quot;yLinkText&quot;:&quot;Novo Nordisk&quot;,&quot;yLinkElement&quot;:&quot;context_link&quot;,&quot;yModuleName&quot;:&quot;content-canvas&quot;,&quot;yTrafficOrigin&quot;:&quot;content-canvas default&quot;}\" target=\"_blank\" rel=\"noopener noreferrer nofollow\">Novo Nordisk<\/a> to improve clinical development in the age of AI.\u00a0  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">The partnership aims to develop proprietary AI-ready data and AI-powered clinical development workflows to further help Novo Nordisk speed up the path from discovery to approval and make its clinical trial operations more efficient. As part of the agreement, H1 will also acquire rights to further advance StudyHub, a leading digital and AI-enabled platform for clinical development built by Novo Nordisk.  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">&#8220;In this age of AI, the way clinical trials should be executed needs to change,&#8221; said Ariel Katz, CEO of H1. &#8220;We are proud to partner with Novo Nordisk to enhance innovation in their clinical trials and to play an important part to bring their life-changing drugs to patients quicker.&#8221;  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">&#8220;H1 is the right partner for this work with its domain expertise, AI-ready proprietary data, and AI technology to advance what we have built at Novo Nordisk,&#8221; said Mishal Patel, Group Vice President, AI &amp; Digital Innovation, R&amp;D at Novo Nordisk. &#8220;This next wave of AI will help us reduce cycle times, address process inefficiencies at scale, and fundamentally improve how we select clinical trial sites and design studies, ultimately enabling better, faster decisions across the development lifecycle.&#8221;  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">H1 is an AI-powered platform that brings healthcare data, domain expertise, and an AI intelligence platform to life science companies.\u00a0  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">Through this collaboration, Novo Nordisk will use H1&#8217;s capabilities to improve its clinical development operational efficiency, with a focus on improving design, site selection and enrollment across clinical trials.  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">About Novo Nordisk  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\"><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=BPCq0phCgvA6wRs6W4_VrkOvZAb2zAd9KmO8siH9t1mJxfKJVezfIr8PPWLhPR-5zSta2hjYwOcN4-eyOrj6o_wN2lPGXQAYbIGhMvIhbkE=\" data-ylk=\"slk:Novo%20Nordisk;elm:context_link;itc:0;sec:content-canvas;source:content-canvas%20default\" data-yga=\"{&quot;yLinkText&quot;:&quot;Novo Nordisk&quot;,&quot;yLinkElement&quot;:&quot;context_link&quot;,&quot;yModuleName&quot;:&quot;content-canvas&quot;,&quot;yTrafficOrigin&quot;:&quot;content-canvas default&quot;}\" target=\"_blank\" rel=\"noopener noreferrer nofollow\">Novo Nordisk<\/a> is a leading global healthcare company founded in 1923 and headquartered in Denmark. Our\u00a0purpose is to drive change to defeat serious chronic diseases built upon our heritage in diabetes.\u00a0We do so by pioneering scientific breakthroughs, expanding access to our medicines,\u00a0and working to prevent and\u00a0ultimately cure\u00a0disease.\u00a0  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">About H1  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\"><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=D7G-IShnQhS2dsspLuUjdlmEEE-oYP6IXsJOKFSGEMZPZJjZVrkskAn7oRJHTLoQ\" data-ylk=\"slk:H1;elm:context_link;itc:0;sec:content-canvas;source:content-canvas%20default\" data-yga=\"{&quot;yLinkText&quot;:&quot;H1&quot;,&quot;yLinkElement&quot;:&quot;context_link&quot;,&quot;yModuleName&quot;:&quot;content-canvas&quot;,&quot;yTrafficOrigin&quot;:&quot;content-canvas default&quot;}\" target=\"_blank\" rel=\"noopener noreferrer nofollow\">H1<\/a> is an AI-powered platform that helps identify and engage the right doctors for critical workflows across pharma, health plan, health system, and technology companies. At the core of the platform is H1&#8217;s Doctor Graph\u2014a structured representation of physician identity, expertise, relationships, and behavioral signals, creating a powerful network effect as it is continuously enriched by participants across the healthcare ecosystem. Built on one of the world&#8217;s largest and most comprehensive global datasets of healthcare professionals, H1 combines deep healthcare data with agentic AI workflows to power critical workflows across drug development, medical and commercial engagement, care navigation, and provider data and network intelligence. Today, 85% of the top 20 pharmaceutical companies and 9 out of 10 of the top health plans trust H1 as a critical partner in building a healthier future for all.  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">Contact  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">Kerry Metzdorf <br \/>kerry@big-swing.com  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">A photo accompanying this announcement is available at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=YAuvzos8rHUCFrm0epcecJuvO4qFgb6BoW5AvtN8L67T98ANdTe4JVmbAaCAE7HZPmof9w_FGVzL2y6LtS9MbJcL41r913vJdgPDgqQc3JpfgaAq-ftbhsSRSkkbHQmtm5KzalTLhQpFM05dTa35ckcAPgrdCESBQXUFgO1lsma9xfYujbbSTeDlpbrmAR2qHKknBXJVIkxdgh0hSbufMDZ97pqdXg-auxFGQEnw8_gxb3FOsoYKzQubejKVqX2eIHqWuu6q9WS36GDCfybNlA==\" data-ylk=\"slk:https%3A%2F%2Fwww.globenewswire.com%2FNewsRoom%2FAttachmentNg%2Ffd5f4528-6a06-4e16-ac18-2cb44ff2394d;elm:context_link;itc:0;sec:content-canvas;source:content-canvas%20default\" data-yga=\"{&quot;yLinkText&quot;:&quot;https:\/\/www.globenewswire.com\/NewsRoom\/AttachmentNg\/fd5f4528-6a06-4e16-ac18-2cb44ff2394d&quot;,&quot;yLinkElement&quot;:&quot;context_link&quot;,&quot;yModuleName&quot;:&quot;content-canvas&quot;,&quot;yTrafficOrigin&quot;:&quot;content-canvas default&quot;}\" target=\"_blank\" rel=\"noopener noreferrer nofollow\">https:\/\/www.globenewswire.com\/NewsRoom\/AttachmentNg\/fd5f4528-6a06-4e16-ac18-2cb44ff2394d<\/a>  <\/p>\n","protected":false},"excerpt":{"rendered":"H1 Partnership builds on Novo Nordisk&#8217;s AI and digital foundation to enhance clinical trial design and execution through&hellip;\n","protected":false},"author":2,"featured_media":190994,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[271],"tags":[26614,14834,86060,57691,86059,272,86058],"class_list":["post-190993","post","type-post","status-publish","format-standard","has-post-thumbnail","category-novo-nordisk","tag-clinical-development","tag-clinical-trial","tag-domain-expertise","tag-h1","tag-healthcare-data","tag-novo-nordisk","tag-proprietary-data"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@dk\/117488780852858323","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/190993","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/comments?post=190993"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/190993\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media\/190994"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media?parent=190993"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/categories?post=190993"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/tags?post=190993"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}